Stock Monitor: Cerus Post Earnings Reporting
LONDON, UK / ACCESSWIRE / March 16, 2018 / Active-Investors.com has just released a free research report on Tyme Technologies, Inc. (NASDAQ: TYME). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/'symbol=TYME as the Company's latest news hit the wire. On March 14, 2018, the Company announced that the US Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application, allowing the Company to initiate the planned Phase-II clinical trial for SM-88 in pancreatic cancer. Tyme will begin patients' enrollment at initial clinical sites over the next few weeks. Register today and get access to over 1,000 Free Research Reports by joining our site below:
www.active-investors.com/registration-sg
Active-Investors.com is currently working on the research report for Cerus Corporation (NASDAQ: CERS), which also belongs to the Healthcare sector as the Company Tyme Technologies. Do not miss out and become a member today for free to access this upcoming report at:
www.active-investors.com/registration-sg/'symbol=CERS
Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Tyme Technologies most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:
www.active-investors.com/registration-sg/'symbol=TYME
The Company is also evaluating SM-88 in an ongoing Phase-II clinical trial for the treatment of prostate cancer, under a separate IND, with final data from that trial expected in the end of 2018.
IND Acceptance Represents Important Accomplishment for Tyme's SM-88 Clinical Development Program
Steven Hoffman, Chief Executive Officer of Tyme, stated that the acceptance of this IND represents an important accomplishment for the Company's SM-88 clinical development program and Tyme hopes to build upon the encouraging results previously observed in SM-88 treated pancreatic cancer patients.
Steven added that Tyme has been aggressively preparing for this trial and interest from well beyond the 35 planned sites for the trial.
Tyme Announced Interim Phase-II Safety and Efficacy Data for SM-88 in Prostate Cancer
On February 08, 2018, the Company presented efficacy and safety data from an ongoing Phase-II trial of SM-88 in patients with non-metastatic, biochemical-recurrent prostate cancer (nmPC) at the 2018 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium in San Francisco, California. Around 13 evaluable patients were assessed from an ongoing Phase-II trial of SM-88 in nmPC with rising prostate-specific antigen levels, detectable circulating tumor cells and no radiographically detectable metastases. Most patients had previously received ADT (androgen deprivation therapy) after radiation therapy or surgery, but ADT treatment was not permitted during the trial.
92% of patients maintained radiographic progression-free survival (rPFS) with a median of 12 months since documented biochemical recurrence, and 10 months since starting SM-88 treatment. 85% patients demonstrated rising or stable testosterone levels, with no drug-related serious adverse events observed. All patients reported stable cognitive and sexual function domain measures.
About SM-88
SM-88 is a potential first-in-class combination therapy that utilizes a proprietary dysfunctional tyrosine derivative to interrupt the metabolic processes of cancer cells, breaking down the cells' key defenses and making them vulnerable to oxidative stress and death. SM-88 has demonstrated efficacy in the treatment of multiple oncology indications, including breast and prostate cancer, without report of significant toxicity or serious adverse events.
About Pancreatic Cancer
Pancreatic cancer arises when cells in the pancreas, a glandular organ behind the stomach, begin to multiply out of control and form a mass. These cancerous cells have the ability to invade other parts of the body. The most common type of pancreatic cancer, pancreatic adenocarcinoma, accounts for about 85% of cases, and the term "pancreatic cancer" is sometimes used to refer only to that type. These adenocarcinomas start within the part of the pancreas which makes digestive enzymes. Signs and symptoms of pancreatic cancer includes yellow skin, abdominal or back pain, unexplained weight loss, light-colored stools, dark urine, and loss of appetite.
About Tyme Technologies, Inc.
Founded in 2011 and headquartered in New York City, New York, Tyme Technologies is a clinical-stage pharmaceutical company which develops novel cancer therapeutics intended to be safe and effective across a broad range of tumor types. The Company maintains a broad intellectual property portfolio of issues and pending patents covering its technologies and products well into the 2030's.
Stock Performance Snapshot
March 15, 2018 - At Thursday's closing bell, Tyme Technologies' stock fell 3.73%, ending the trading session at $2.32.
Volume traded for the day: 446.52 thousand shares, which was above the 3-month average volume of 338.19 thousand shares.
Stock performance in the past twelve-month period - up 14.29%
After yesterday's close, Tyme Technologies' market cap was at $203.35 million.
The stock is part of the Healthcare sector, categorized under the Biotechnology industry.
Active-Investors:
Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
A-I has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
NO WARRANTY
A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.
CONTACT
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: info@active-investors.com
Phone number: 73 29 92 6381
Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: Active-Investors
